Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone.

The experimental drug pirfenidone (PFD) has been evaluated as an inhibitor of keloid proliferation and compared with triamcinolone (TAC) injections by studying the involution of active human keloid implants in athymic nude mice (nu-nu). PFD was fed to mice with keloid implants at a level of 2.75 mg/g of feed.

Implants of keloid and hypertrophic scars into the athymic nude mouse: changes in the glycosaminoglycans of the implants.

Studies have been made of the glycosaminoglycan (GAG) composition of implants of keloid and hypertrophic scars in athymic nude mice in order to evaluate these implants as a model for studies of causation and therapy of these abnormal human scars. Changes in weight of implanted tissue were also recorded. Pieces of keloid, hypertrophic scar or normal human skin were placed in subcutaneous pockets of athymic nude mice and left for various times up to 246 days.

Implants of hypertrophic scars and keloids into the nude (athymic) mouse: viability and morphology.

Pieces of hypertrophic scars and keloids were implanted into subcutaneous pockets of nude (athymic) mice and carried for varying times up to 246 days. No rejection phenomena were observed. Microvascular anastomosis occurred between host and implant within the first several days.

Characterization of implants from Dupuytren's contracture tissue into the nude (athymic) mouse.

Dupuytren's contracture tissues were obtained from six patients as excess surgical material. Pieces of these tissues (a total of 38 implants) were placed into subcutaneous pockets in the suprascapular area of nude (athymic) mice. The objective was to determine whether the implant tissues would be maintained in the mouse with the characteristics of Dupuytren's tissue.